Latest Novo Nordisk Stories
PRINCETON, N.J., April 2, 2012 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that the U.S. Food and Drug Administration (FDA) has approved Levemir(®) (insulin detemir [rDNA origin] injection) for a pregnancy Category B classification, indicating that Levemir(®), when used in pregnant women with diabetes, did not increase the risk of harm to the unborn baby. To view the multimedia assets associated with this release, please click:...
NEW YORK, March 5, 2012 /PRNewswire/ -- Attorneys at Sanford Wittels & Heisler, LLP ("SWH") today filed a $70 million class and collective action complaint in the U.S. District Court for the Southern District of New York (SDNY) on behalf of two plaintiffs and a class of sales representatives ("reps") currently or formerly employed by Danish Pharmaceutical manufacturer, Novo Nordisk, Inc. The complaint demands $70 million in overtime pay and charges that Novo willfully fails to...
MONMOUTH COUNTY, N.J., Feb. 21, 2012 /PRNewswire/ -- Cinderella's Closet of Monmouth County in cooperation with Novo Nordisk, Inc. will host a Prom Boutique on Saturday, March 3, 2012 from 9:00 am to 3:00 pm at Novo Nordisk's 1100 Campus Road location in Princeton. The Prom Boutique is open to high school students who are in need of prom attire and who have limited financial means. Cinderella's Closet is a non-profit 501 (c) (3) organization that was founded five years ago by two...
The green lifestyle site encourages people to take responsibility for their own health. New York, NY (PRWEB) January 28, 2012 People everywhere are up in arms over the recent announcement from celebrity chef Paula Deen on the "Today Show" that she has type 2 diabetes and is partnering with diabetes drug maker Novo Nordisk. The green lifestyle site, eco18.com, recently released an article on the news and is shifting the blame from Deen to individuals who knowingly make poor food choices...
PRINCETON, N.J., Jan. 23, 2012 /PRNewswire/ -- Novo Nordisk (NYSE:NVO) announced today that the company will establish a type 1 diabetes research and development center in Seattle, Wash., U.S. The new center will combine Novo Nordisk's history of innovation and leadership in diabetes treatment with the company's growing expertise in immunotherapy. "Novo Nordisk has been passionate about helping people fight diabetes since the company was founded, and it is part of our mission to...
PRINCETON, N.J., Jan. 19, 2012 /PRNewswire/ -- Novo Nordisk (NYSE: NVO), the world leader in diabetes care, has been ranked 43rd in FORTUNE magazine's 2012 "100 Best Companies to Work For" list. Reflecting the passion of Novo Nordisk's employees, the company has been highlighted on the list for four consecutive years. (Logo: http://photos.prnewswire.com/prnh/20110414/NY80976LOGO ) "I'm convinced that it is our people who set us apart. Each and every person at Novo Nordisk...
PRINCETON, N.J., Jan. 17, 2012 /PRNewswire/ -- Novo Nordisk, the world leader in diabetes care, is teaming up with American cooking stars Paula Deen and her sons, Bobby and Jamie Deen, to launch Diabetes in a New Light((TM)), a national initiative to help adults find simple ways to manage everyday challenges associated with type 2 diabetes. To view the multimedia assets associated with this release, please click:...
SAN DIEGO, Jan. 4, 2012 /PRNewswire/ -- Elevation Pharmaceuticals, Inc. announced today the closing of a $30 million Series B financing, led by new investor Novo Ventures, to fund development of Elevation's new aerosol therapy for patients living with chronic obstructive pulmonary disease (COPD). All previous investors participated in the round, including Canaan Partners, TPG Biotech, Care Capital and Mesa Verde Venture Partners. In conjunction with this financing, Elevation has...
The world diabetes care devices market was worth USD 16.2 billion last year and is forecast to grow at a CAGR of 6% to reach USD 24.3 billion in 2017. New market research report “Asia-Pacific Diabetes Care Devices Market Outlook to 2017 - Glucose Monitoring and Insulin Delivery” developed by GlobalData has been recently published by Market Publishers Ltd. London, UK (PRWEB) December 28, 2011 The world diabetes care devices market was worth USD 16.2 billion last year and is forecast to...
BOSTON, Dec. 15, 2011 /PRNewswire/ -- Enlight Biosciences LLC announced today that it has formed new partnerships with AstraZeneca and Novo Nordisk. As partners in Enlight, AstraZeneca and Novo Nordisk will have the opportunity to collaborate and invest in the development of potentially transformational technologies with application to their therapeutic programs. Enlight was created by PureTech Ventures in partnership with major pharmaceutical companies and academic luminaries to...
